J&J’s Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with high-risk smoldering multiple myeloma, a precursor to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

UVIX stock analysis and why UVIX stock is ready to move higher with the VIX

September 8, 2023

Evotec reports Q1 2024 results and provides corporate update – Biotech Investments

EQS-News: Evotec SE / Key word(s): Quarterly / Interim Statement Evotec reports Q1 2024 results and provides corporate update 22.05.2024 / 07:00 CET/CEST The issuer

May 23, 2024

AI-powered method predicts protein dynamics to accelerate drug discovery

Understanding the structure of proteins is critical for demystifying their functions and developing drugs that target them.

March 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.